Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health
By Amit Chowdhry ● Oct 22, 2024
Terray Therapeutics, a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced Series B funding of $120 million. The funding round was led by new investor Bedford Ridge Capital and existing investor NVentures (NVIDIA’s venture capital arm), with participation from new and existing investors, including Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. Sid Shenai partnered with Bedford Ridge Capital on this financing and will join Terray’s Board of Directors.